What are the pharmacological effects of serpatinib?

The pharmacological effect of serpatinib is mainly reflected in its highly selective inhibitory effect on the tyrosine kinase of theRET receptor. The primary target of serpatinib is the RET receptor tyrosine kinase. The RET gene is normally involved in neural interstitial development, but in some tumors, such as non-small cell lung cancer and thyroid cancer, the RET gene undergoes fusions or mutations, resulting in continued cell activation and driving tumor growth. Serpatinib can efficiently and persistently bind to the tyrosine kinase domain of the RET receptor, thereby blocking its downstream signaling, cutting off the growth signals of tumor cells, and achieving anti-tumor effects.

By specifically inhibiting the activity of RET kinase, serpatinib not only directly inhibits the function of RET gene fusion protein, but also blocks the resulting tumor signaling pathways, such as PI3K/AKT, RAS/RAF/MEK/ERK, etc. Blockade of these signaling pathways plays a key role in inhibiting the proliferation, invasion and metastasis of tumor cells. Therefore, serpatinib can significantly inhibit the growth and spread of tumors and provide effective treatment options for tumor patients.

In addition to inhibiting tumor growth and spread, serpatinib can induce tumor cell apoptosis. By blocking the signaling of RET receptors, serpatinib can trigger the apoptosis program inside tumor cells, thereby promoting the death of tumor cells. This mechanism of action helps reduce tumor burden and improve treatment efficacy.

In clinical trials, serpatinib demonstrated good safety and tolerability. Although some patients may experience side effects such as fatigue, muscle pain, nausea, etc., these side effects are usually mild and controllable. Doctors will adjust the drug dosage and treatment plan according to the patient's specific conditions to ensure the safety and effectiveness of the drug.

References:

https://synapse.patsnap.com/article/what-is-the-mechanism-of-selpercatinib